Best Practices for Nuclear Medicine during the Covid-19 Pandemic
As the world deals with the Covid-19 pandemic there is little time to reflect on best practices in nuclear medicine. As we move beyond today’s acute threat and move into the recovery phase, we will look back and review how we handled the situation. One group in Wuhan, China, where the disease originated, is doing just that. The nuclear medicine team published an article in the European Journal of Nuclear Medicine and Molecular Imaging https://www.auntminnie.com/index.aspx?sec=sup&sub=mol&pag=dis&ItemID=128597 in which they describe the appropriate management of patients, equipment and scheduling during this pandemic in an effort to contain the spread of the disease
Investment in Mo-99 production continues to expand in the USA
Janesville, Wisconsin’s SHINE Medical Technologies LLC, announced it has secured an additional $50 million in capital financing from Oaktree Capital Management of Los Angeles. Having raised over $200 million from investors and grants, SHINE broke ground on its new facility in May of this year and expects to be producing Mo-99 in 2022. The company forecasts this facility will meet as much as one third of the world’s requirement for Mo-99. https://www.bizjournals.com/milwaukee/news/2019/10/08/shine-medical-secures-50m-in-additional-funding.html?ana=smartbrief